6-K
Table of Contents

Securities and Exchange Commission

Washington, D.C. 20549

 

 

Form 6-K

 

 

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d/16 of

the Securities Exchange Act of 1934

February 2018

 

 

AEGON N.V.

 

 

Aegonplein 50

2591 TV THE HAGUE

The Netherlands


Table of Contents

Aegon’s condensed consolidated interim financial statements 4Q 2017, dated February 14, 2018, are included as appendix and incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   AEGON N.V.
  

 

   (Registrant)

Date: February 15, 2018

   By   

/s/ J.H.P.M. van Rossum

     

J.H.P.M. van Rossum

     

Head of Corporate Financial Center


Table of Contents

LOGO

“Condensed Consolidated Interim Financial Statements 4 Q 2 0 17 The Haque, February 15, 2018 EGON To help people achieve a lifetime of financial security Transform Tomorrow


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     1     

    

 

Table of contents

 

Condensed consolidated income statement

     2  

Condensed consolidated statement of comprehensive income

     3  

Condensed consolidated statement of financial position

     4  

Condensed consolidated statement of changes in equity

     5  

Condensed consolidated cash flow statement

     6  

Notes to the Condensed consolidated interim financial statements

     7  

 

 

 

 

Unaudited    LOGO


Table of Contents

    

     2     

    

  

 

Condensed consolidated income statement                
                                     

EUR millions

    Notes       4Q 2017       4Q 2016       FY 2017       FY 2016  
     

Premium income

    4       6,044       6,118       22,826       23,453  

Investment income

    5       1,791       1,927       7,338       7,788  

Fee and commission income

      932       607       2,802       2,408  

Other revenues

            1       3       7       7  

Total revenues

      8,768       8,654       32,973       33,655  

Income from reinsurance ceded

    6       650       1,011       4,288       3,687  

Results from financial transactions

    7       6,070       429       20,108       15,949  

Other income

    8       189       2       540       66  

Total income

      15,677       10,097       57,910       53,357  
     

Benefits and expenses

    9       14,855       9,453       54,978       51,550  

Impairment charges / (reversals)

    10       36       41       42       95  

Interest charges and related fees

      121       89       435       347  

Other charges

    11       193       18       235       700  

Total charges

      15,205       9,601       55,689       52,693  
     

Share in profit / (loss) of joint ventures

      41       34       161       137  

Share in profit / (loss) of associates

            4       1       11       3  

Income / (loss) before tax

      517       531       2,393       805  

Income tax (expense) / benefit

    12       469       (61     (32     (219

Net income / (loss)

            986       470       2,361       586  
     

Net income / (loss) attributable to:

             

Owners of Aegon N.V.

      986       470       2,361       586  

Non-controlling interests

                                       
     

Earnings per share (EUR per share)

    20              

Basic earnings per common share

      0.46       0.21       1.08       0.22  

Basic earnings per common share B

      0.01       0.01       0.03       0.01  

Diluted earnings per common share

      0.46       0.21       1.08       0.22  

Diluted earnings per common share B

            0.01       0.01       0.03       0.01  

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     3     

    

 

Condensed consolidated statement of comprehensive income

 

               
EUR millions   4Q 2017     4Q 2016     FY 2017     FY 2016  
     

Net income / (loss)

    986       470       2,361       586  
     

Other comprehensive income:

           

Items that will not be reclassified to profit or loss:

           

Changes in revaluation reserve real estate held for own use

    2       6       8       8  

Remeasurements of defined benefit plans

    (34     912       224       (392

Income tax relating to items that will not be reclassified

    (102     (250     (166     86  
     

Items that may be reclassified subsequently to profit or loss:

           

Gains / (losses) on revaluation of available-for-sale investments

    (397     (2,508     1,283       854  

Gains / (losses) transferred to the income statement on disposal and impairment of available-for-sale investments

    (93     (7     (1,330     (2,122

Changes in cash flow hedging reserve

    (71     (782     (853     (54

Movement in foreign currency translation and net foreign investment hedging reserve

    (305     988       (2,149     69  

Equity movements of joint ventures

    (8     1       (15     9  

Equity movements of associates

    1       -       (5     3  

Disposal of group assets

    7       -       7       -  

Income tax relating to items that may be reclassified

    768       1,089       951       225  

Other

    8       9       9       12  

Total other comprehensive income / (loss) for the period

    (224     (543     (2,038     (1,301

Total comprehensive income / (loss)

    762       (73     323       (715
     

Total comprehensive income / (loss) attributable to:

           

Owners of Aegon N.V.

    762       (81     327       (729

Non-controlling interests

    -       8       (3     15  

 

Unaudited    LOGO


Table of Contents

    

     4     

    

  

 

Condensed consolidated statement of financial position

 

 
            Dec. 31,
2017
    Dec. 31,
2016
 

EUR millions

    Notes                  
   

Assets

       

Cash and cash equivalents

      10,768       11,347  

Assets held for sale

    26       5,249       8,705  

Investments

    13       137,172       156,813  

Investments for account of policyholders

    14       194,063       203,610  

Derivatives

    15       5,912       8,318  

Investments in joint ventures

      1,712       1,614  

Investments in associates

      308       270  

Reinsurance assets

    16       19,202       11,208  

Deferred expenses

    18       10,135       11,423  

Other assets and receivables

      10,137       10,805  

Intangible assets

    19       1,633       1,820  

Total assets

      396,291       425,935  
   

Equity and liabilities

       

Shareholders’ equity

      20,573       20,913  

Other equity instruments

            3,794       3,797  

Issued capital and reserves attributable to owners of Aegon N.V.

      24,366       24,710  

Non-controlling interests

            20       23  

Group equity

      24,386       24,734  
   

Subordinated borrowings

      764       767  

Trust pass-through securities

      133       156  

Insurance contracts

    21       110,818       119,569  

Insurance contracts for account of policyholders

    22       122,168       120,929  

Investment contracts

    23       16,943       19,572  

Investment contracts for account of policyholders

    24       74,434       84,774  

Derivatives

    15       7,130       8,878  

Borrowings

    25       13,635       13,153  

Liabilities held for sale

    26       5,003       8,816  

Other liabilities

            20,878       24,588  

Total liabilities

 

            371,904       401,201  

Total equity and liabilities

            396,291       425,935  

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     5     

    

 

Condensed consolidated statement of changes in equity

 

 
EUR millions   Share
capital 1
    Retained
earnings
    Revaluation
reserves
   

Remeasurement

of defined

benefit plans

    Other
reserves
   

Other equity

instruments

   

Issued

capital and

reserves 2

   

Non-
controlling

interests

    Total  
       

Year ended December 31, 2017

                       
       

At beginning of year

    8,193       7,812       5,381       (1,820     1,347       3,797       24,710       23       24,734  
       

Net Income / (loss) recognized in the income statement

    -       2,361       -       -       -       -       2,361       -       2,361  
       

Other comprehensive income:

                       

Items that will not be reclassified to profit or loss:

                       

Changes in revaluation reserve real estate held for own use

    -       -       8       -       -       -       8       -       8  

Remeasurements of defined benefit plans

    -       -       -       224       -       -       224       -       224  

Income tax relating to items that will not be reclassified

    -       -       9       (175     -       -       (166     -       (166
       

Items that may be reclassified subsequently to profit or loss:

                       

Gains / (losses) on revaluation of available-for-sale investments

    -       -       1,283       -       -       -       1,283       -       1,283  

Gains / (losses) transferred to income statement on disposal and impairment of available-for-sale investments

    -       -       (1,330     -       -       -       (1,330     -       (1,330

Changes in cash flow hedging reserve

    -       -       (853     -       -       -       (853     -       (853

Movement in foreign currency translation and net foreign investment hedging reserves

    -       -       (452     102       (1,800     -       (2,149     -       (2,149

Equity movements of joint ventures

    -       -       -       -       (15     -       (15     -       (15

Equity movements of associates

    -       -       -       -       (5     -       (5     -       (5

Disposal of group assets

    -       -       -       -       7       -       7       -       7  

Income tax relating to items that may be reclassified

    -       -       874       -       76       -       951       -       951  

Other

    -       13       -       -       -       -       13       (3     9  

Total other comprehensive income

    -       13       (461     151       (1,737     -       (2,034     (3     (2,038
       

Total comprehensive income I (loss) for 2017

    -       2,374       (461     151       (1,737     -       327       (3     323  

Shares issued

    3       -       -       -       -       -       3       -       3  

Issuance and purchase of (treasury) shares

    -       (105     -       -       -       -       (105     -       (105

Dividends paid on common shares

    (142     (296     -       -       -       -       (439     -       (439

Dividend withholding tax reduction

    -       2       -       -       -       -       2       -       2  

Coupons on non-cumulative subordinated notes

    -       (28     -       -       -       -       (28     -       (28

Coupons on perpetual securities

    -       (103     -       -       -       -       (103     -       (103

Incentive plans

    -       4       -       -       -       (4     (1     -       (1

At end of period

    8,053       9,659       4,920       (1,669     (390     3,794       24,366       20       24,386  
       

Year ended December 31, 2016

                       
       

At beginning of year

    8,387       8,075       6,471       (1,532     1,283       3,800       26,485       9       26,494  
       

Net income / (loss) recognized in the income statement

    -       586       -       -       -       -       586       -       586  

Other comprehensive income:

                   

Items that will not be reclassified to profit or loss:

                   

Changes in revaluation reserve real estate held for own use

    -       8       -       -       -       -       8       -       8  
       

Remeasurements of defined benefit plans

    -       -       -       (392     -       -       (392     -       (392

Income tax relating to items that will not be reclassified

    -       -       (3     89       -       -       86       -       86  

Items that may be reclassified subsequently to profit or loss:

                       

Gains / (losses) on revaluation of available-for-sale investments

    -       -       854       -       -       -       854       -       854  

Gains / (losses) transferred to income statement on disposal and impairment of available-for-sale investments

    -       -       (2,122     -       -       -       (2,122     -       (2,122
       

Changes in cash flow hedging reserve

    -       -       (54     -       -       -       (54     -       (54

Movement in foreign currency translation and net foreign investment hedging reserves

    -       -       (38     16       91       -       69       -       69  

Equity movements of joint ventures

    -       -       -       -       9       -       9       -       9  

Equity movements of associates

    -       -       -       -       3       -       3       -       3  

Income tax relating to items that may be reclassified

    -       -       264       -       (39     -       225       -       225  

Other

    -       (2     -       -       -       -       (2     14       12  

Total other comprehensive income

    -       (2     (1,090     (288     64       -       (1,315     14       (1,301

Total comprehensive Income I (loss) for 2016

      584       (1,090     (288     64       -       (729     15       (715
       

Shares issued

    1       -       -       -       -       -       1       -       1  

Shares withdrawn

    (10     (372     -       -       -       -       (382     -       (382

Issuance and purchase of (treasury) shares

    -       (27     -       -       -       -       (27     -       (27

Dividends paid on common shares

    (186     (304     -       -       -       -       (490     -       (490

Dividend withholding tax reduction

    -       (2     -       -       -       -       (2     -       (2

Coupons on non-cumulative subordinated notes

    -       (28     -       -       -       -       (28     -       (28

Coupons on perpetual securities

    -       (105     -       -       -       -       (105     -       (105

Incentive plans

    -       (9     -       -       -       (3     (12     -       (12

At end of period

    8,193       7,812       5,381       (1,820     1,347       3,797       24,710       23       24,734  

 

1  For a breakdown of share capital please refer to note 20.
2  Issued capital and reserves attributable to owners of Aegon N.V.

 

Unaudited    LOGO


Table of Contents

    

     6     

    

  

 

Condensed consolidated cash flow statement  
EUR millions   FY 2017     FY 2016  
   

Cash flow from operating activities

    554       3,319  
   

Purchases and disposals of intangible assets

    (34     (22

Purchases and disposals of equipment and other assets

    (67     (66

Purchases and disposals of businesses and subsidiaries

    (1,107     95  

Purchases, disposals and dividends joint ventures and associates

    10       (1,085

Cash flow from investing activities

    (1,198     (1,078
   

Issuance of treasury shares

    2       (623

Purchase of treasury shares

    (266     -  

Dividends paid

    (294     (306

Issuances, repurchases and coupons of perpetuals

    (138     (140

Issuances, repurchases and coupons of non-cumulative subordinated notes

    (37     (38

Issuances and repayments of borrowings

    1,252       641  

Cash flow from financing activities

    519       (465
   

Net increase I (decrease) in cash and cash equivalents

    (125     1,776  

Net cash and cash equivalents at January 1

    11,347       9,593  

Effects of changes in foreign exchange rates

    (196     (23

Net cash and cash equivalents at end of period

    11,026       11,346  
                    

Cash and cash equivalents

    10,768       11,347  

Cash and cash equivalents classified as Assets held for sale

    259       -  

Bank overdrafts classified as other liabilities

    (2     (1

Net cash and cash equivalents

    11,026       11,346  

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     7     

    

 

Notes to the Condensed consolidated interim financial statements

Amounts in EUR millions, unless otherwise stated

Aegon N.V., incorporated and domiciled in the Netherlands, is a public limited liability company organized under Dutch law and recorded in the Commercial Register of The Hague under number 27076669 and with its registered address at Aegonplein 50, 2591 TV, The Hague, the Netherlands. Aegon N.V. serves as the holding company for the Aegon Group and has listings of its common shares in Amsterdam and New York.

Aegon N.V. (or ‘the Company’) and its subsidiaries (‘Aegon’ or ‘the Group’) have life insurance and pensions operations in more than 20 countries in the Americas, Europe and Asia and are also active in savings and asset management operations, accident and health insurance, general insurance and to a limited extent banking operations. Headquarters are located in The Hague, the Netherlands. The Group employs over 28,000 people worldwide.

1. Basis of presentation

The condensed consolidated interim financial statements as at and for the period ended, December 31, 2017, have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’, as adopted by the European Union (hereafter ‘IFRS’). They do not include all of the information required for a full set of financial statements prepared in accordance with IFRS and should therefore be read together with the 2016 consolidated financial statements of Aegon N.V. as included in Aegon’s Annual Report for 2016. Aegon’s Annual Report for 2016 is available on its website (aegon.com). Aegon’s 2017 consolidated financial statements will be published on March 23, 2018.

The condensed consolidated interim financial statements have been prepared in accordance with the historical cost convention as modified by the revaluation of investment properties and those financial instruments (including derivatives) and financial liabilities that have been measured at fair value. Certain amounts in prior periods may have been reclassified to conform to the current year presentation. These reclassifications had no effect on net income, shareholders’ equity or earnings per share. The condensed consolidated interim financial statements as at, and for the period ended December 31, 2017, were approved by the Supervisory Board on February 14, 2018.

The condensed consolidated interim financial statements are presented in euro (EUR) and all values are rounded to the nearest million unless otherwise stated. The consequence is that the rounded amounts may not add up to the rounded total in all cases.

The published figures in these condensed consolidated interim financial statements are unaudited.

 

Unaudited    LOGO


Table of Contents

    

     8     

    

  

 

2. Significant accounting policies

All accounting policies and methods of computation applied in the condensed consolidated interim financial statements are the same as those applied in the 2016 consolidated financial statements.

New IFRS accounting standards effective

The following standards, interpretations, amendments to standards and interpretations became effective in 2017 and have been endorsed by the European Union:

 

t   IAS 7 Amendment Disclosure initiative;
t   IAS 12 Recognition of Deferred Tax Assets for Unrealised Losses; and
t   Annual improvements 2014-2016 Cycle.

None of these revised standards and interpretations are significantly impacting the financial position or the condensed consolidated interim financial statements.

For a complete overview of IFRS standards, published before January 1, 2017, that will be applied in future years, and were not early adopted by the Group, please refer to Aegon’s Annual Report for 2016.

Future adoption of IFRS accounting standards

In May 2017, the IASB has issued IFRS 17 Insurance Contracts. IFRS 17 will be mandatorily effective for annual reporting periods beginning on or after January 1, 2021. It aims to provide a more consistent accounting model for insurance contracts among entities issuing insurance contracts globally. IFRS 17, together with IFRS 9 Financial Instruments, will fundamentally change the accounting in IFRS financial statements of insurance companies. Aegon has started its implementation project on both standards. Aegon expects the impact of these standards to be significant.

The endorsement process of the European Union of the new standard has started in 2017. A final endorsement decision is not expected to be made in 2018.

In October 2017, the IASB has issued IFRS 16 Leases. This Standard was endorsed by the European Union in October 2017. IFRS 16 will be mandatorily effective for annual reporting periods beginning on or after January 1, 2019. Aegon is evaluating the impact that adoption of this Standard is expected to have on the Group’s financial statements.

Taxes

Taxes on income for the year ended December 31, 2017, are calculated using the tax rate that is estimated to be applicable to total annual earnings.

Judgments and critical accounting estimates

Preparing the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions, including the likelihood, timing or amount of future transactions or events, that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from the estimates made.

In preparing the condensed consolidated interim financial statements, significant judgments made by management in applying the Group’s accounting policies and the key sources of estimating uncertainty were not significantly different than those that were applied to the consolidated financial statements as at, and for the year ended, December 31, 2016, other than mentioned in paragraph 3.1 Impact from 2017 assumption changes and model updates.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     9     

    

 

Exchange rates

Assets and liabilities of foreign operations are translated to the presentation currency at the closing rates on the reporting date. Income, expenses and capital transactions (such as dividends) are translated at average exchange rates or at the prevailing rates on the transaction date, if more appropriate. The following exchange rates are applied for the condensed consolidated interim financial statements:

Closing exchange rates

 

                      USD      GBP  

December 31, 2017

     1        EUR        1.2008        0.8877  

December 31, 2016

     1        EUR        1.0548        0.8536  

Weighted average exchange rates

 

                         USD        GBP  

Year ended December 31, 2017

     1        EUR        1.1291        0.8758  

Year ended December 31, 2016

     1        EUR        1.1069        0.8187  

3. Segment information

3.1 Income statement

EUR millions   Americas     The
Netherlands
    United
Kingdom
    Central &
Eastern
Europe
    Spain &
Portugal
    Europe     Asia     Asset
Management
    Holding and
other
activities
    Eliminations     Segment
total
    Joint
ventures and
associates
eliminations
    Consolidated  

Three months ended December 31, 2017

                           
     

Underlying earnings before tax

    352       135       23       14       (6     167       12       37       (42     -       525       16       541  

Fair value items

    81       37       (17     -       -       20       (1     -       (14     -       85       (21     64  

Realized gains / (losses) on investments

    38       22       30       (1     -       51       2       -       -       -       91       -       91  

Impairment charges

    (26     (12     -       -       -       (12     (1     -       -       -       (39     -       (39

Impairment reversals

    2       2       -       -       -       2       -       -       -       -       4       -       4  

Other Income I (charges)

    (266     206       (40     -       -       166       -       (47     16       -       (132     (4     (136

Run-off businesses

    (8     -       -       -       -       -       -       -       -       -       (8     -       (8

Income I (loss) before tax

    172       389       (4     14       (6     393       12       (10     (40       526       (9     517  

Income tax (expense) / benefit

    523       (55     (2     (2     -       (58     -       (11     5       -       460       9       469  

Net Income I (loss)

    695       334       (5     12       (5     335       12       (21     (35     -       986       -       986  

Inter-segment underlying earnings

    (20     (27     (19     (2     -       (49     2       48       19       -          
     

Revenues

                           

Life Insurance gross premiums

    1,823       441       2,854       104       57       3,457       233       -       2       (2     5,512       (96     5,416  

Accident and health insurance

    485       28       8       -       -       36       21       -       -       -       542       (3     539  

General insurance

    -       35       -       53       29       117       -       -       -       -       117       (29     88  

Total gross premiums

    2,308       504       2,862       158       86       3,609       254       -       -       (2     6,170       (127     6,043  

Investment income

    765       524       432       12       9       978       61       1       69       (68     1,806       (15     1,791  

Fee and commission Income

    717       66       58       12       6       142       16       164       -       (50     989       (57     932  

Other revenues

    1       -       -       -       -       -       -       -       1       -       2       (1     1  

Total revenues

    3,791       1,094       3,352       182       101       4,730       331       165       72       (120     .8,968       (200     8,768  

Inter-segment revenues

    -       -       -       -       -       -       -       51       70                                  

 

EUR millions   Americas     The
Netherlands
    United
Kingdom
    Central &
Eastern
Europe
    Spain &
Portugal
    Europe     Asia     Asset
Management
    Holding and
other
activities
    Eliminations     Segment
total
    Joint
ventures and
associates
eliminations
    Consolidated  

Three months ended December 31, 2016

                           
     

Underlying earnings before tax

    388       134       23       14       3       174       13       35       (54     (3     554       17       571  

Fair value items

    (226     202       (31     -       (1     171       (11     -       53       -       (13     (22     (35

Realized gains / (losses) on investments

    (18     47       4       -       1       52       2       -       -       -       36       (1     35  

Impairment charges

    (3     (8     -       (1     -       (9     -       (5     -       -       (17     -       (17

Impairment reversals

    8       8       -       -       -       8       -       -       -       -       16       -       16  

Other income I (charges)

    (27     34       (20     (23     -       (9     -       (1     (1     -       (38     -       (38

Run-off businesses

    (1     -       -       -       -       -       -       -       -       -       (1     -       (1

Income I (loss) before tax

    121       418       (24     (10     3       387       5       28       (2     (3     536       (5     531  

Income tax (expense) I benefit

    35       (91     19       (8     (2     (81     (14     (10     4       -       (66     5       (61

Net Income / (loss)

    157       326       (4     (18     1       306       (9     18       2       (3     470       -       470  

Inter-segment underlying earnings

    (53     (25     (17     (3     -       (45     18       60       20            
     

Revenues

                           

Life Insurance gross premiums

    1,958       400       2,739       102       58       3,299       309       -       -       (21     5,546       (112     5,433  

Accident and health Insurance

    548       29       8       -       -       37       24       -       (4     -       605       (1     604  

General insurance

    -       36       -       44       23       103       -       -       1       (1     103       (23     80  

Total gross premiums

    2,506       465       2,746       147       81       3,439       333       -       (2     (22     6,254       (137     6,118  

Investment Income

    970       487       396       12       16       910       62       1       102       (101     1,944       (16     1,927  

Fee and commission Income

    408       88       30       9       4       131       15       157       -       (62     649       (42     607  

Other revenues

    2       -       -       -       1       1       -       -       1       -       4       (1     3  

Total revenues

    3,886       1,040       3,172       168       101       4,482       410       157       101       (185     8,851       (197     8,654  

Inter-segment revenues

    -       -       -       -       -       1       20       62       103                                  

 

Unaudited    LOGO


Table of Contents

    

     10     

    

  

 

EUR millions   Americas     The
Netherlands
   

United

Kingdom

   

Central &

Eastern

Europe

   

Spain &

Portugal

    Europe     Asia    

Asset

Management

   

Holding and
other

activities

    Eliminations     Segment
total
   

Joint
ventures and

associates

eliminations

    Consolidated  

Year ended December 31, 2017

                           
     

Underlying earnings before tax geographically

    1,381       520       116       67       4       707       49       136       (170     -       2,103       61       2,163  

Fair value items

    170       (112     (82     -       -       (194     -       -       24       -       -       (97     (97

Realized gains I (losses) on investments

    157       184       62       1       -       248       4       3       -       -       413       (5     408  

Impairment charges

    (38     (27     -       (2     -       (29     (1     -       (3     -       (71     -       (71

Impairment reversals

    22       10       -       -       -       10       -       -       -       -       32       -       32  

Other income I (charges)

    (353     296       40       -       -       336       (19     (49     16       -       (68     (4     (72

Run-off businesses

    30       -       -       -       -       -       -       -       -       -       30       -       30  

Income (loss) before tax

    1,369       872       137       66       4       1,078       33       90       (134     -       2,437       (44     2,393  

Income tax (expense) I benefit

    198       (162     (56     (9     (6     (233     (28     (42     29       -       (76     44       (32

Net Income / (loss)

    1,567       710       81       57       (2     846       5       48       (105     -       2,361       -       2,361  

Inter-segment underlying earnings

    (78     (111     (87     (11     (1     (209     (1     214       73            
     

Revenues

                           

Life insurance gross premiums

    7,437       1,857       9,603       411       208       12,079       983       -       7       (9     20,498       (546     19,952  

Accident and health insurance

    2,115       203       32       1       83       319       97       -       -       -       2,531       (20     2,511  

General insurance

    -       148       -       216       103       467       -       -       1       (1     466       (103     363  

Total gross premiums

    9,553       2,208       9,635       628       394       12,865       1,080       -       8       (10     23,496       (670     22,826  

Investment income

    3,368       2,172       1,517       49       37       3,774       246       4       295       (291     7,396       (58     7,338  

Fee and commission income

    1,919       326       235       43       17       621       63       609       -       (221     2,991       (189     2,802  

Other revenues

    5       -       -       -       3       3       1       -       4       -       13       (5     7  

Total revenues

    14,844       4,706       11,387       720       450       17,263       1,390       613       308       (522     33,895       (922     32,973  

lnter-seqment revenues

    -       (1     -       -       -       -       3       222       298                                  

 

EUR
millions
  Americas     The
Netherlands
   

United

Kingdom

   

Central &

Eastern

Europe

   

Spain &

Portugal

    Europe     Asia    

Asset

Management

   

Holding and
other

activities

    Eliminations     Segment
total
   

Joint
ventures and

associates

eliminations

    Consolidated  

Year ended December 31, 2016

                           
     

Underlying earnings before tax geographically

    1,249       534       59       55       8       655       21       149       (162     -       1,913       48       1,960  

Fair value items

    (521     (33     (7       (1     (41     (9     -       (74     -       (645     (72     (717

Realized gains I (losses) on investments

    (13     189       153       -       (1     342       8       3       -       -       340       (6     334  

Impairment charges

    (72     (29     -       -       -       (27     (1     (5     (7     1       (113     -       (112

Impairment reversals

    42       17       -       -       -       17       -       -       -       (1     58       -       58  

Other income I (charges)

    (100     44       (678     (23     -       (658     (5     (2     (6     -       (771     -       (771

Run-off businesses

    54       -       -       -       -       -       -       -       -       -       54       -       54  

Income I (loss) before tax

    638       721       (474     34       6       288       14       145       (249     -       836       (31     805  

Income tax (expense) I benefit

    (80     (155     18       (15     (8     (161     (27     (48     65       -       (250     31       (219

Net Income I (loss)

    558       566       (456     19       (2     127       (13     97       (183     -       586       -       586  

Inter-segment underlying earnings

    (194     (95     (87     (14     (1     (197     74       234       84            
     

Revenues

                           

Life insurance gross premiums

    7,363       2,015       9,888       399       191       12,493       1,121       -       6       (84     20,898       (498     20,400  

Accident and health insurance

    2,204       210       36       1       73       320       104       -       (4     -       2,624       (15     2,609  

General insurance

    -       266               179       92       536               -       5       (5     536       (92     444  

Total gross premiums

    9,567       2,491       9,924       578       355       13,348       1,225       -       7       (89     24,058       (606     23,453  

investment income

    3,717       2,135       1,661       45       45       3,886       232       3       406       (403     7,841       (54     7,788  

Fee and commission income

    1,651       350       95       36       14       495       61       632       -       (242     2,596       (188     2,408  

Other revenues

    4       -       -       -       2       2               1       3               11       (4     7  

Total revenues

    14,940       4,976       11,680       659       416       17,732       1,517       636       416       (734     34,507       (852     33,655  

Inter-segment revenues

    -       3       -       -       -       3       79       243       409                                  

Impact from 2017 assumption changes and model updates

In 2017, a charge of EUR 276 million (2016: EUR 118 million charge) has been recorded in other income/ (charges) in respect of assumption changes and model updates. The impact is mainly attributable to Aegon’s business in the Americas and the Netherlands. Assumption changes and model updates in the Americas led to a net negative impact of EUR 402 million and were mainly driven by a charge of EUR 303 million (USD 343 million) from the conversion of the largest block of universal life business to a new model, of which EUR 56 million (USD 63 million) was recorded in the fourth quarter. The model allows for modeling policyholder behavior and other assumptions on a policy by policy basis, whereas in the previous model this was done at a cohort level. A model change in fixed annuities discount rate, resulted in a charge of EUR 44 million (USD 50 million) and other assumption changes and model updates led to a charge of EUR 54 million (USD 61 million). In the Netherlands, assumption changes and model updates led to a gain of EUR 101 million, which mainly relates to the guarantee provision.

3.2 Performance measure

Aegon’s segment information is prepared by consolidating on a proportionate basis Aegon’s joint ventures and associated companies.

Performance measure

A non-IFRS performance measure of reporting segments utilized by the Company is underlying earnings before tax. Underlying earnings before tax reflects Aegon’s profit from underlying business operations and excludes components that relate to accounting mismatches that are dependent on market volatility, updates to best estimate actuarial and economic assumptions and model updates or events that are considered outside the normal course of business.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     11     

    

 

Aegon believes that its non-lFRS performance measure, underlying earnings before tax, provides meaningful supplemental information about the underlying results of Aegon’s business, including insight into the financial measures that Aegon’s senior management uses in managing the business. Among other things, Aegon’s senior management is compensated based in part on Aegon’s results against targets using underlying earnings before tax. While many other insurers in Aegon’s peer group present substantially similar performance measures, the performance measures presented in this document may nevertheless differ from the performance measures presented by other insurers. There is no standardized meaning to these measures under IFRS or any other recognized set of accounting standards.

The reconciliation from underlying earnings before tax to income before tax, being the most comparable IFRS measure, is presented in the tables in this note.

The items that are excluded from underlying earnings before tax as described further below are: fair value items, realized gain or losses on investments, impairment charges/reversals, other income or charges, run-off businesses and share in earnings of joint ventures and associates.

Fair value items

Fair value items include the over- or underperformance of investments and guarantees held at fair value for which the expected long-term return is included in underlying earnings before tax.

In addition, hedge ineffectiveness on hedge transactions, fair value changes on economic hedges without natural offset in earnings and for which no hedge accounting is applied and fair value movements on real estate are included under fair value items.

Certain assets held by Aegon are carried at fair value and managed on a total return basis, with no offsetting changes in the valuation of related liabilities. These include assets such as investments in hedge funds, private equities, real estate (limited partnerships), convertible bonds and structured products. Underlying earnings before tax exclude any over- or underperformance compared to management’s long-term expected return on assets. Based on current holdings and asset returns, the long-term expected return on an annual basis is 7-10%, depending on asset class, including cash income and market value changes. The expected earnings from these asset classes are net of deferred policy acquisition costs (DPAC) where applicable.

In addition, certain products offered by Aegon Americas contain guarantees and are reported on a fair value basis and the total return annuities and guarantees on variable annuities. The earnings on these products are impacted by movements in equity markets and risk-free interest rates. Short-term developments in the financial markets may therefore cause volatility in earnings. Included in underlying earnings before tax is a long-term expected return on these products and excluded is any over- or underperformance compared to management’s expected return.

The fair value movements of certain guarantees and the fair value change of derivatives that hedge certain risks on these guarantees of Aegon the Netherlands, VA Europe (included in United Kingdom) and Japan are excluded from underlying earnings before tax, and the long-term expected return for these guarantees is set at zero. In addition, fair value items include market related results on our loyalty bonus reserves in the United Kingdom. The value of these reserves are directly related to policyholder investments which value is directly impacted by movements in equity and bond markets.

Holding and other activities include certain issued bonds that are held at fair value through profit or loss (FVTPL). The interest rate risk on these bonds is hedged using swaps. The fair value movement resulting from changes in Aegon’s credit spread used in the valuation of these bonds are excluded from underlying earnings before tax and reported under fair value items.

 

Unaudited    LOGO


Table of Contents

    

     12     

    

  

 

Realized gains or losses on investments

Includes realized gains and losses on available-for-sale investments, mortgage loans and other loan portfolios.

Impairment charges/reversals

Impairment charges include impairments on available-for-sale debt securities, shares including the effect of deferred policyholder acquisition costs, mortgage loans and other loan portfolios at amortized cost, joint ventures and associates. Impairment reversals include reversals on available-for-sale debt securities.

Other income or charges

Other income or charges includes: a) items which cannot be directly allocated to a specific line of business; b) the impact of actuarial and economic assumption and model updates used to support calculations of our liabilities for insurance and investment contracts sold to policyholders and related assets; and c) items that are outside the normal course of business, including restructuring charges. In the condensed consolidated interim financial statements, these restructuring charges are included in operating expenses. Actuarial assumption and model updates are recorded in Claims and Benefits in the IFRS income statement.

Run-off businesses

Includes underlying results of business units where management has decided to exit the market and to run-off the existing block of business. This line includes results related to the run-off of the institutional spread-based business, structured settlements blocks of business, bank-owned and corporate-owned life insurance (BOLl/COLl) business (until April 1, 2017, please refer to note 29 Acquisitions/ divestments for more information on the divestment of this business), and the remaining reinsurance business. Aegon has other blocks of business for which sales have been discontinued and of which the earnings are included in underlying earnings before tax.

Share in earnings of joint ventures and associates

Earnings from Aegon’s joint ventures in the Netherlands, Mexico, Spain, Portugal, China and Japan and Aegon’s associates in India, Brazil, the Netherlands, United Kingdom, Mexico and France are reported on an underlying earnings before tax basis.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     13     

    

 

3.3 Investments

Amounts included in the tables on investments are presented on an IFRS basis. which means that investments in joint ventures and associates are not consolidated on a proportionate basis. Instead, these investments are included on a single line using the equity method of accounting.

December 31, 2017   Americas     The
Netherlands
    United
Kingdom
    Central &
Eastern
Europe
    Spain &
Portugal
    Europe     Asia     Asset
Management
   

Holdings

and other
activities

    Eliminations    

EUR millions

 

Total

EUR

 

Investments

                         

Shares

    567       859       5       54       5       924       1       2       57       -       1,551  

Debt securities

    54,535       21,411       1,779       712       646       24,548       5,252       9       -       -       84,344  

Loans

    8,831       30,557       -       275       54       30,886       6       -       13       -       39,736  

Other financial assets

    8,904       21       228       10       -       259       67       146       20       -       9.395  

Investments In real estate

    633       1,495       -       4       15       1,513       -       -       -       -       2,147  

Investments general account

    73,469       54,343       2,011       1,055       720       58,130       5,326       157       91       -       137,172  

Shares

    -       9,262       15,856       244       14       25.376       -       -       -       (6     25.370  

Debt securities

    3,116       13,370       8,125       216       9       21,720       -       -       -       -       24,836  

Unconsolidated investment funds

    99,426       276       33,476       873       81       34,706       -       -       -       -       134,132  

Other financial assets

    422       3,788       4,850       11       1       8,650       -       -       -       -       9,072  

Investments In real estate

    -       -       655       -       -       655       -       -       -       -       655  

Investments for account of policyholders

    102,964       26,697       62,961       1,343       105       91,105       -       -       -       (6     194,063  

Investments on balance sheet

    176,434       81,040       64,972       2,398       825       149,235       5,326       157       91       (6     331,236  

Off balance sheet investments third parties

    212,736       1,759       114,906       5,709       528       122,902       2,718       143,923       -       (981     481,297  

Total revenue generating investments

    389,170       82,799       179,878       8,107       1,353       272,137       8,043       144,079       91       (987     812,533  

Investments

                         

Available-for-sale

    59,459       19,841       2,007       756       651       23,256       5,299       137       20       -       88,170  

Loans

    8,831       30,557         275       54       30,886       6       -       13       -       39,736  

Financial assets at fair value through profit or loss

    107,511       29,147       62,310       1,363       105       92,925       21       20       57       (6     200,528  

Investments in real estate

    633       1,495       655       4       15       2,168                                       2,801  

Total investments on balance sheet

    176,434       81,040       64,972       2,398       825       149,235       5,326       157       91       (6     331,236  

Investments in joint ventures

    6       1,008       -       -       480       1,488       118       99       1       -       1,712  

Investments In associates

    77       74       7       6       -       88       14       122       8       -       308  

Other assets

    35.728       15,221       8,352       383       189       24,131       2,347       242       29.836       (29.263     63,034  

Consolidated total assets

    212,245       97,343       73,331       2,787       1,494       174,941       7,805       620       29,936       (29,270     396,291  

 

December 31, 2016   Americas     The
Netherlands
    United
Kingdom
    Central &
Eastern
Europe
    Spain &
Portugal
    Europe     Asia     Asset
Management
    Holdings
and other
activities
    Eliminations    

EUR millions

 

Total

EUR

 

Investments

                         

Shares

    793       334       84       35       4       457       -       2       62       -       1,314  

Debt securities

    70,766       23,741       2,036       633       683       27,093       5,310       -       -       -       103,169  

loans

    10,820       28,627       -       303       45       28,975       18       -       -       -       39,812  

Other financial assets

    9.924       358       115       10       -       483       -       88       23       -       10,519  

Investments in real estate

    743       1,238       -       3       15       1,256       -       -       -       -       1,999  

Investments general account

    93,046       54,298       2,236       983       747       58,264       5,328       90       85       -       156,813  

Shares

    -       9,689       15,503       295       13       25,499       -       -       -       (7     25,492  

Debt securities

    4,779       15,434       9,847       235       10       25,526       -       -       -           30,305  

Unconsolidated Investment funds

    102,534       -       36,600       879       64       37,543       -       -       -       -       140,077  

Other financial assets

    27       2,862       4,150       9       1       7,022       -       -       -       -       7,049  

Investments in real estate

    -       -       686       -       -       686       -       -       -       -       686  

Investments for account of policyholders

    107,341       27,985       66,786       1,418       88       96,276       -       -       -       (7     203,610  

Investments on balance sheet

    200,387       82,283       69,021       2,401       834       154,540       5,328       90       85       (7     360,423  

Off balance sheet investments third parties

    240,072       952       5,333       3,154       507       9,946       2,734       130,889       -       (864     382,776  

Total revenue generating investments

    440,458       83,235       74,354       5,556       1,342       164,487       8,061       130,979       85       (871     743,200  

investments

                         

Avallable-for-sale

    77,918       23,044       2,152       660       687       26,544       5,289       87       23       -       109,860  

loans

    10,820       28,627       -       303       45       28,975       18       -       -       -       39,812  

Financial assets at fair value through profit or loss

    110,906       29,374       66,183       1,436       88       97,080       21       4       62       (7     208,066  

Investments in real estate

    743       1,238       686       3       15       1,942               -       -       -       2,685  

Total investments on balance sheet

    200,387       82,283       69,021       2,401       834       154,540       5,328       90       85       (7 )·      360,423  

Investments in joint ventures

    7       877       -       -       495       1,373       134       99       -       -       1,614  

Investments In associates

    95       21       8       2       -       30       21       125       (1     -       270  

Other assets

    31,003       15,260       12,718       293       170       28,426       3,122       293       31,107       (30.338     63,627  

Consolidated total assets

    231,493       98,441       81,747       2,696       1,500       184,370       8,604       607       31,192       (30,345     425,935  

 

Unaudited    LOGO


Table of Contents

    

     14     

    

  

 

4. Premium income and premiums paid to reinsurers

 

                              

EUR millions

    4Q 2017       4Q 2016       FY 2017       FY 2016  
   

Premium income

         

Life insurance

    5,417       5,433       19,952       20,400  

Non-life insurance

    627       684       2,874       3,053  

Total premium income

    6,044       6,118       22,826       23,453  

Accident and health insurance

    539       604       2,511       2,609  

General insurance

    88       80       363       444  

Non-life Insurance premium income

    627       684       2,874       3,053  
   

Premiums paid to reinsurers 1

         

Life insurance

    839       821       3,214       2,932  

Non-life insurance

    46       52       217       244  

Total premiums paid to reinsurers

    885       874       3,431       3,176  

Accident and health insurance

    42       55       205       238  

General insurance

    4       (3     13       7  

Non-life Insurance paid to reinsurers

    46       52       217       244  
1  Premiums paid to reinsurers are recorded within Benefits and expenses in the income statement - refer to note 9 - Benefits and expenses.

Premium income Life insurance includes EUR 1.739 million for 4Q 2017 and EUR 5,139 million for FY 2017 (4Q 2016: EUR 1,692 million, FY 2016 EUR 5,255 million) of premiums related to insurance policies upgraded to the retirement platform in the UK.

5. Investment income

 

                              

EUR millions

    4Q 2017       4Q 2016       FY 2017       FY 2016  

Interest income

    1,429       1,573       6,052       6,479  
     

Dividend income

    337       321       1,164       1,180  

Rental income

    25       34       121       129  

Total investment income

    1,791       1,927       7,338       7,788  
     

Investment income related to general account

    1,274       1,407       5,394       5,737  

Investment income for account of policyholders

    517       520       1,944       2,051  

Total

    1,791       1,927       7,338       7,788  

6. Income from reinsurance ceded

The income from reinsurance ceded for the full year of 2017 increased by EUR 601 million compared to the full year of 2016. This is mainly the result of the reinsurance transaction, related to the pay-out annuity and BOLI/COLI businesses in the Americas that took place in the second quarter of the year, partly offset by the reduction of income from reinsurance ceded in the UK, due to the Part VII transfers of annuity insurance policies to Rothesay Life and Legal & General, which were completed the second and third quarter respectively. Due to the transaction regarding the pay-out annuity and BOLI/COLI businesses in the Americas, the liabilities for insurance contracts increased by EUR 0.9 billion resulting from loss recognition and then were ceded to a reinsurance company. The loss recognition is reflected in the benefits and expenses line (within claims and benefits) and is offset by an equal increase in the income from reinsurance ceded. As a result there is a nil net impact in the income statement. For more details on the divestment of the pay-out annuity and BOLl/COLI businesses and the Part VII transfers of Rothesay Life and Legal & General refer to note 29 Acquisitions/divestments.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     15     

    

 

7. Results from financial transactions

 

                              

EUR millions

    4Q 2017       4Q 2016       FY 2017       FY 2016  
     

Net fair value change of general account financial investments at FVTPL other than derivatives

    148       (21     232       (42

Realized gains /(Iosses) on financial investments

    78       40       431       327  

Gains /(Iosses) on investments in real estate

    53       18       193       70  

Net fair value change of derivatives

    159       24       (1,301     435  

Net fair value change on for account of policyholder financial assets at FVTPL

    5,616       344       20,524       15,121  

Net fair value change on investments in real estate for account of policyholders

    13       1       38       (26

Net foreign currency gains /(Iosses)

    (5     9       (20     41  

Net fair value change on borrowings and other financial liabilities

    6       13       10       21  

Realized gains /(Iosses) on repurchased debt

    1       -       1       1  

Total

    6,070       429       20,108       15,949  

Net fair value change on for account of policyholder financial assets at FVTPL for full year of 2017 increased compared to the full year of 2016, mainly from favorable equity markets results which were partly offset by losses from interest rates movements. The increase of the net fair value change on for account of policyholder financial assets at FVTPL in 4Q 2017 compared to 4Q 2016 is mainly driven by stronger equity markets.

Net fair value change on for accounts of policyholder financial assets at FVTPL is offset by amounts in the Claims and benefits line reported in note 9 Benefits and expenses.

8. Other income

Other income for the full year 2017 of EUR 540 million mainly related to a book gain of EUR 231 million (USD 250 million) from the divestment of the pay-out annuity and the BOLl/COLI businesses in the Americas recorded in the second quarter and a book gain of EUR 208 million on the sale of the Unirobe Meeùs Groep on November 1st, 2017 by Aegon the Netherlands, recorded in the fourth quarter. Furthermore, a release of an expense reserve of EUR 82 million (GBP 71 million) was recorded in the second quarter that was embedded in the liabilities for insurance contracts following the completion of the Part VII transfer to Rothesay Life. In the third quarter EUR 17 million (GBP 14 million) related to the completion of the Part VII transfer of annuities reinsured to Legal & General in 2016 was included. For more details on the divestment of the pay-out annuity and the BOLl/COLI businesses, the sale of the Unirobe Meeùs Groep and the completion of the Part VII transfer to Rothesay Life and Legal & General refer to note 29 Acquisitions/divestments.

9. Benefits and expenses

 

                              

EUR millions

    4Q 2017       4Q 2016       FY 2017       FY 2016  
     

Claims and benefits

    14,043       8,504       51,714       48,128  

Employee expenses

    555       583       2,234       2,287  

Administration expenses

    370       342       1,424       1,273  

Deferred expenses

    (225     (288     (980     (1,203

Amortization charges

    112       313       586       1,065  

Total

    14,855       9,453       54,978       51,550  

The following table provides an analysis of “claims and benefits”:

 

                              

EUR millions

    4Q 2017       4Q 2016       FY 2017       FY 2016  
     

Benefits and claims paid life

    6,163       7,592       23,634       23,877  

Benefits and claims paid non-life

    453       478       1,903       2,052  

Change in valuation of liabilities for insurance contracts

    6,437       601       22,741       16,193  

Change in valuation of liabilities for investment contracts

    (534     (1,734     (2,644     (104

other

    (9     (5     (34     (45
     

Policyholder claims and benefits

    12,511       6,932       45,599       41,974  

Premium paid to reinsurers

    885       874       3,431       3,176  

Profit sharing and rebates

    5       10       23       49  

Commissions

    642       689       2,661       2,929  

Total

    14,043       8,504       51,714       48,128  

 

Unaudited    LOGO


Table of Contents

    

     16     

    

  

 

The lines “change in valuation of liabilities for insurance contracts” and “change in valuation of liabilities for investment contracts” reflect changes in technical provisions resulting from net fair value changes on for account of policyholder financial assets at fair value through P&L included in Results from financial transactions (note 7) of EUR 5,616 million for 4Q 2017 and EUR 20,524 million for FY 2017 (4Q 2016: EUR 344 million, FY 2016: EUR 15,121 million). In addition, the line “change in valuation of liabilities for insurance contracts” includes an increase of technical provisions for life insurance contracts of EUR 508 million for 4Q 2017 and EUR 601 million for FY 2017 (4Q 2016: decrease of EUR 1,115 million, FY 2016: increase of EUR 2,349 million).

10. Impairment charges/(reversals)

                              

EUR millions

    4Q 2017       4Q 2016       FY 2017       FY 2016  
     

Impairment charges / (reversals) comprise:

         

Impairment charges on financial assets, excluding receivables

    41       18       74       117  

Impairment reversals on financial assets, excluding receivables

    (4     (16     (32     (58

Impairment charges / (reversals) on non-financial assets and receivables

    (1     39       -       36  

Total

    36       41       42       95  
     

Impairment charges on financial assets, excluding receivables, from:

         

Shares

    1       -       2       1  

Debt securities and money market instruments

    6       6       17       53  

Loans

    33       2       50       23  

Other

    -       10       -       33  

Investments in associates

    1       -       4       7  

Total

    41       18       74       117  
     

Impairment reversals on financial assets, excluding receivables, from:

         

Debt securities and money market instruments

    (2     (12     (17     (42

Loans

    (2     (3     (13     (14

Other

    -       (1     (2     (2

Total

    (4     (16     (32     (58

11. Other charges

Other charges in 2017 of EUR 235 million mainly relate to the loss of EUR 105 million (USD 119 million) regarding the divestment of a block of life reinsurance business to SCOR in the Americas in December 2017 and a charge of EUR 83 million (USD 100 million), regarding a provision in anticipation of a possible settlement in connection with a previously disclosed investigation by the US Securities and Exchange Commission (SEC), both recorded in the fourth quarter. In the third quarter an impairment of deferred transaction costs of EUR 36 million (GBP 32 million) was recorded as a result of the sale of Aegon Ireland plc, which is subject to customary regulatory approvals. For more details on the divestment of a block of US reinsurance run off business to SCOR and Aegon Ireland plc. refer to note 29 Acquisitions/divestments.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     17     

    

 

12. Income tax (expense)/ benefit

Income tax in 2017 is impacted by a one-time benefit resulting from the US tax reform. In the Americas, the corporate income tax rate decreased from 35% to 21% as from January 1, 2018. A one-time benefit is driven by a reduction in net deferred tax liabilities as at December 31, 2017 and amounts to EUR 554 million (USD 626 million). Deferred tax liabilities are included in Other liabilities in the statement of financial position.

13. Investments

 

                

EUR millions

    Dec. 31, 2017       Dec. 31, 2016  
   

Available-for-sale (AFS)

    88,170       109,860  

Loans

    39,736       39,812  

Financial assets at fair value through profit or loss (FVTPL)

    7,119       5,142  

Financial assets, for general account, excluding derivatives

    135,026       154,814  

Investments in real estate

    2,147       1,999  

Total investments for general account, excluding derivatives

    137,172       156,813  

 

       

Financial assets, for general account, excluding derivatives

       

EUR millions

    AFS       FVTPL       Loans       Total  
   

Shares

    490       1,062       -       1,551  

Debt securities

    80,200       4,144       -       84,344  

Money market and other short-term investments

    6,690       119       -       6,809  

Mortgages loans

    -       -       33,930       33,930  

Private loans

    -       -       3,642       3,642  

Deposits with financial institutions

    -       -       139       139  

Policy loans

    -       -       1,897       1,897  

Other

    791       1,795       127       2,713  

December 31, 2017

    88,170       7,119       39,736       135,026  
   
      AFS       FVTPL       Loans       Total  
   

Shares

    824       490       -       1,314  

Debt securities

    101,054       2,115       -       103,169  

Money market and other short-term investments

    6,776       317       -       7,093  

Mortgages loans

    -       -       34,206       34,206  

Private loans

    -       -       3,166       3,166  

Deposits with financial institutions

    -       -       129       129  

Policy loans

    -       -       2,207       2,207  

Other

    1,206       2,219       104       3,529  

December 31, 2016

    109,860       5,142       39,812       154,814  

The decrease of EUR 19.8 billion in financial assets, for general account, excluding derivatives compared to December 31, 2016 is mainly driven by the disposal of debt securities related to the divestments of the pay-out annuity and BOLl/COLI businesses and the block of life reinsurance to SCOR in the Americas. In addition, the balance is affected by foreign exchange rates translation adjustments.

 

Unaudited    LOGO


Table of Contents

    

     18     

    

  

 

14. Investments for account of policyholders

                        

EUR millions

  Dec. 31, 2017           Dec. 31, 2016

Shares

  25,370     25,492

Debt securities

  24,836     30,305

Money market and short-term investments

  2,340     1,231

Deposits with financial institutions

  2,946     2,951

Unconsolidated investment funds

  134,132     140,077

Other

  3,786           2,868

Total investments for account of policyholders at fair value through profit or loss, excluding derivatives

  193,409     202,924

Investment in real estate

  655           686

Total investments for account of policyholders

  194,063           203,610

15. Derivatives

The movements in fair value of derivatives on both the asset and liability side of the condensed consolidated statement of financial position mainly result from changes in interest rates and other market movements during the period, as well as purchases, disposals and maturities. The divestment of the pay-out annuity and BOLI/COLI businesses in the Americas contributed to the decrease of derivative assets with EUR 259 million compared to December 31, 2016.

16. Reinsurance assets

Reinsurance assets increased by EUR 8.0 billion compared to December 31, 2016 mainly due to the reinsurance transaction, related to the pay-out annuity and BOLI/COLI businesses in the Americas that took place in the second quarter of the year. For more details on the divestment of these businesses refer to note 29 Acquisitions/divestments.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     19     

    

 

17. Fair value

The following tables provide an analysis of financial instruments recorded at fair value on a recurring basis by level of the fair value hierarchy:

 

 

Fair value hierarchy

 

                           
         
EUR millions   Level I     Level II     Level III     Total  

As at December 31, 2017

           
     

Financial assets carried at fair value

           

Available-far-sale investments

           

Shares

    51       151       288       490  

Debt securities

    26,338       52,415       1,447       80,200  

Money markets and other short-term instruments

    1,664       5,026       -       6,690  

Other investments at fair value

    -       208       583       791  

Total Available-far-sale investments

    28,053       57,800       2,318       88,170  
     

Fair value through profit or loss

           

Shares

    226       232       604       1,062  

Debt securities

    1,964       2,175       4       4,144  

Money markets and other short-term instruments

    17       102       -       119  

Other investments at fair value

    1       539       1,255       1,795  

Investments for account of policyholders 1

    115,323       76,302       1,784       193,409  

Derivatives

    68       5,787       57       5,912  

Total Fair value through profit or loss

    117,599       85,137       3,705       206,440  

Total financial assets at fair value

    145,652       142,937       6,022       294,610  
     

Financial liabilities carried at fair value

           

Investment contracts for account of policyholders 2

    -       36,950       219       37,169  

Borrowings 3

    -       536       -       536  

Derivatives

    34       5,251       1,845       7,130  

Total financial liabilities at fair value

    34       42,738       2,064       44,835  
     

As at December 31, 2016

           
     

Financial assets carried at fair value

           

Available-for-sale investments

           

Shares

    119       312       393       824  

Debt securities

    29,386       69,702       1,966       101,054  

Money markets and other short-term instruments

    -       6,776       -       6,776  

Other investments at fair value

    -       453       754       1,206  

Total Available-for-sale investments

    29,504       77,243       3,112       109,860  
     

Fair value through profit or loss

           

Shares

    288       152       50       490  

Debt securities

    27       2,082       6       2,115  

Money markets and other short-term instruments

    -       317       -       317  

Other investments at fair value

    1       961       1,257       2,219  

Investments for account of policyholders 1

    125,997       75,202       1,726       202,924  

Derivatives

    41       8,169       108       8,318  

Total Fair value through profit or loss

    126,355       86,883       3,146       216,384  

Total financial assets at fair value

    155,860       164,126       6,259       326,244  
     

Financial liabilities carried at fair value

           

Investment contracts for account of policyholders 2

    -       42,627       176       42,803  

Borrowings 3

    -       610       -       610  

Derivatives

    64       6,347       2,467       8,878  

Total financial liabilities at fair value

    64       49,584       2,643       52,290  

1 The investments for account of policyholders included in the table above represents only those investments carried at fair value through profit or loss.

2 The investment contracts for account of policyholders included in the table above represents only those investment contracts carried at fair value.

3 Total borrowings on the statement of financial position contain borrowings carried at amortized cost that are not included in the above schedule.

 

Unaudited    LOGO


Table of Contents

    

     20     

    

  

 

Significant transfers between Level l, Level II and Level III

Aegon’s policy is to record transfers of assets and liabilities between Level l, Level II and Level III at their fair values as of the beginning of each reporting period.

The table below shows transfers between Level l and II for financial assets and financial liabilities recorded at fair value on a recurring basis during the year ended December 31, 2017.

 

Fair value transfers                            
EUR millions   FY 2017     FY 2016  
     Transfers
Level I to
Level II
    Transfers
Level II to
Level I
    Transfers
Level I to
Level II
    Transfers
Level II to
Level I
 

Financial assets carried at fair value

           

Available-for-sale investments

           

Shares

    1       1       -       -  

Debt securities

    12           5       69  

Money markets and other short-term instruments

    -       1,664       -       -  

Total

    13       1,666       5       69  
     

Fair value through profit or loss

           

Shares

    124       19       -       -  

Investments for account of policyholders

    12       30       3       (1

Total

    136       49       3       (1

Total financial assets at fair value

    149       1,714       8       68  
     

Financial liabilities carried at fair value

           

Investment contracts for account of policyholders

    1       -       -       -  

Total financial liabilities at fair value

    1       -       -       -  

Transfers are identified based on transaction volume and frequency, which are indicative of an active market.

In the fourth quarter EUR 1.7 billion short term money market funds were reported as level l, whereas these instrumens have been reported as level II investments previously. Historically, short term money market funds have been set to amortized cost (which has equated to market value). In the fourth quarter their pricing methodology has changed to the active market transaction price and therefore these instruments are now being reported as level I.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     21     

    

 

Movements in Level III financial instruments measured at fair value

The following table summarizes the change of all assets and liabilities measured at estimated fair value on a recurring basis using significant unobservable inputs (‘Level III’), including realized and unrealized gains (losses) of all assets and liabilities and unrealized gains (losses) of all assets and liabilities still held at the end of the respective period.

 

Roll forward of Level III financial instruments                                                          
EUR millions   January 1,
2017
    Total gains /
losses in
income
statement 1
   

Total gains /

losses in OCI 2

    Purchases     Sales     Settlements     Net
exchange
differences
    Reclassification     Transfers
from Level I
and Level II
    Transfers
to Level I
and Level II
    Transfers to
disposal
groups
    December 31,
2017
    Total unrealized
gains and losses for
the period recorded
in the P&L for
instruments held at
December 31, 2017 ³
 

Financial assets carried at fair value available-for-sale Investments

                             

Shares

    393       54       (46     68       (112     (35     (34     -       -       -       -       288       -  

Debt securities

    1,966       39       (2     678       (149     (890     (186     -       203       (211     -       1,447       -  

Other Investments at fair value

    754       (112     (109     194       (48     (9     (87     -       1       -       -       583       -  
      3,112       (19     (158     939       (309     (935     (307     -       205       (211     -       2,318       -  
     

Fair value through profit or loss

                             

Shares

    50       (11     -       583       (18     -       -       -       -       -       -       604       (11

Debt securities

    6       -       -       -       -       -       (1     -       -       -       -       4       1  

Other investments at fair value

    1,257       23       -       378       (350     -       (162     -       341       (233     -       1,255       20  

Investments for account of policyholders

    1,726       11       -       671       (622     -       (27     -       32       (8     -       1,784       30  

Derivatives

    108       (33     -       -       -       -       (2     (16     -       -       -       57       (21
      3,146       (10     -       1,633       (989     -       (191     (16     374       (241     -       3,705       19  
     

Financial liabilities carried at fair value

                             

Investment contracts for account of policyholders

    176       7       -       60       (21     -       (12     -       10       (2     -       219       (2

Derivatives

    2,467       (828     -       -       300       -       (75     10       -       -       (30     1,845       (745
      2,643       (821     -       60       279       -       (87     10       10       (2     (30     2,064       (747

 

EUR millions   January 1,
2016
    Total gains /
losses in
income
statement 1
   

Total gains /

losses in OCI 2

    Purchases     Sales     Settlements     Net
exchange
differences
    Reclassification     Transfers
from Level I
and Level II
    Transfers
to Level I
and Level II
    Transfers to
disposal
groups
    December 31,
2016
    Total unrealized
gains and losses for
the period recorded
in the P&L for
instruments held at
December 31, 2017 ³
 
     

Financial assets carried at fair value available-for-sale Investments

                             

Shares

    293       27       (7     161       (92     (1     11       -       -       -       -       393       -  

Debt securities

    4,144       1       92       443       (262     (287     39       -       651       (2,854     -       1,966       -  

Other investments at fair value

    928       (177     20       240       (133     (141     18       -       -       (1     -       754       -  
      5,365       (150     105       845       (487     (429     68       -       651       (2,856     -       3,112       -  
     

Fair value through profit or loss

                             

Shares

    -       3       -       48       -       -       -       -       -       -       -       50       3  

Debt securities

    6       (1     -       -       -       -       -       -       -       -       -       6       -  

Other investments at fair value

    1,265       (44     -       178       (277     -       35       -       419       (321     -       1,257       (42

Investments for account of policyholders

    1,745       22       -       469       (395     -       (35     -       8       (88     -       1,726       23  

Derivatives

    222       (285     -       75       108       -       (12     -       -       -       -       108       (287
      3,239       (305     -       770       (564     -       (11     -       427       (409     -       3,146       (303
     

Financial liabilities carried at fair value

                             

Investment contracts for account of policyholders

    156       (14     -       45       (12     -       2       -       -       (2     -       176       -  

Derivatives

    2,104       542       -       -       (207     -       28       -       -       -       -       2,467       562  
      2,260       528       -       45       (219     -       31       -       -       (2     -       2,643       563  

1 Includes impairments and movements related to fair value hedges. Gains and losses are recorded In the line item results from financial transactions of the income statement.

2 Total gains and losses are recorded in line items Gains/ (losses) on revaluation of available-for-sale investments and (Gains)/ Iosses transferred

to the Income statement on disposal and impairment of available-for-sale investment of the statement of other comprehensive Income.

3 Total gaIns / (losses) for the period during which the financial instrument was in Level III.

During 2017, Aegon transferred certain financial instruments from Level I and II to Level III of the fair value hierarchy. The reason for the change in level was that the market liquidity for these securities decreased, which led to a change in market observability of prices. Prior to transfer, the fair value for the Level II securities was determined using observable market transactions or corroborated broker quotes respectively for the same or similar instruments. The amount of assets and liabilities transferred to Level III was EUR 589 million (FY 2016: EUR 1,077 million). Since the transfer, all such assets have been valued using valuation models incorporating significant non market-observable inputs or uncorroborated broker quotes.

Similarly, during 2017, Aegon transferred EUR 454 million (FY 2016: EUR 3,266 million) of financial instruments from Level III to other levels of the fair value hierarchy. The change in level was mainly the result of a return of activity in the market for these securities and that for these securities the fair value could be determined using observable market transactions or corroborated broker quotes for the same or similar instruments.

 

Unaudited    LOGO


Table of Contents

    

     22     

    

  

 

The following table presents information about the significant unobservable inputs used for recurring fair value measurements for certain Level III financial instruments.

 

Overview of significant unobservable inputs              
EUR millions   Carrying
amount December 31,
2017
        Valuation technique 1       Significant unobservable
input 2
        Range (weighted average)  

Financial assets carried at fair value available-for-sale investments

         

Shares

    231     Net asset value 4     n.a.       n.a.  
      57     Other     n.a.       n.a.  
      288                      
   

Debt securities

         
      1,034     Broker quote     n.a.       n.a.  
      116     Discounted cash flow     Credit spread       1.04% - 2.72% (2.64%)  
      297     Other     n.a.       n.a.  
      1,447                      
   

Other investments at fair value

         

Tax credit investments

    528     Discounted cash flow     Discount rate       5.8%  

Investment funds

    31     Net asset value 4     n.a.       n.a.  

Other

    24     Other     n.a.       n.a.  

December 31, 2017

    583                      

    

                           
   

Fair value through profit or loss

         

Shares

    604     Other     n.a.       n.a.  

Debt securities

    4     Other     n.a.       n.a.  
      609                      
   

Other investments at fair value

         

Investment funds

    1,246     Net asset value 4     n.a.       n.a.  

Other

    9     Other     n.a.       n.a.  
      1,255                      
   

Derivatives

         

Longevity swap

    24     Discounted cash flow     Mortality       n.a.  

Other

    30     Other     n.a.       n.a.  

December 31, 2017

    54                      

Total financial assets at fair value 3

    4,236                      
   

Financial liabilities carried at fair value

         

Derivatives

         

Embedded derivatives in insurance contracts

    1,831     Discounted cash flow     Own Credit spread       0.20% - 0.30% (0.22%)  

Longevity swap

    10     Oiscounted cash flow     Mortality       n.a.  

Other

    3     Other     n.a.       n.a.  

Total financial liabilities at fair value

    1,845                      

1 other in the table above (column Valuation technique) includes investments for which the fair value is uncorroborated and no broker quote is received.

2 Not applicable (n.a.) has been included when no significant unobservable assumption has been identified.

3 Investments for account of policyholders are excluded from the table above and from the disclosure regarding reasonably possible alternative assumptions. Policyholder assets, and their returns, belong to policyholders and do not impact Aegon’s net income or equity. The effect on total assets is offset by the effect on total liabilities. Derivatives exclude derivatives for account of policyholders amounting to EUR3 million.

4 Net asset value is considered the best approximation to the fair value of these financial instruments.

The description of Aegon’s methods of determining fair value is included in the consolidated financial statements for 2016. For reference purposes, the valuation techniques included in the table above are described in more detail on the following pages.

Shares

When available, Aegon uses quoted market prices in active markets to determine the fair value of its investments in shares. Fair values for unquoted shares are estimated using observations of the price/earnings or price/cash flow ratios of quoted companies considered comparable to the companies being valued. Valuations are adjusted to account for company-specific issues and the lack of liquidity inherent in an unquoted investment. Adjustments for illiquidity are generally based on available market evidence. In addition, a variety of other factors are reviewed by management, including, but not limited to, current operating performance, changes in market outlook and the third-party financing environment.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     23     

    

 

Available-for-sale shares include shares in a Federal Home Loan Bank (FHLB) for an amount of EUR 204 million (December 31, 2016: EUR 237 million) that are measured at par, which are reported as part of Other in the column Valuation technique. A FHLB has implicit financial support from the United States government. The redemption value of the shares is fixed at par and they can only be redeemed by the FHLB.

Debt securities

Aegon’s portfolio of debt securities can be subdivided in Residential mortgage-backed securities (RMBS), Commercial mortgage-backed securities (CMBS), Asset-backed securities (ABS), Corporate bonds and Government debt. Below relevant details in the valuation methodology for these specific types of debt securities are described.

Valuations of RMBS, CMBS and ABS are monitored and reviewed on a monthly basis. Valuations per asset type are based on a pricing hierarchy which uses a waterfall approach that starts with market prices from indices and follows with third-party pricing services or brokers. The pricing hierarchy is dependent on the possibilities of corroboration of the market prices. If no market prices are available, Aegon uses internal models to determine fair value. Significant inputs included in the internal models are generally determined based on relative value analyses, which incorporate comparisons to instruments with similar collateral and risk profiles. Market standard models may be used to model the specific collateral composition and cash flow structure of each transaction.

Valuations of corporate bonds are monitored and reviewed on a monthly basis. The pricing hierarchy is dependent on the possibility of corroboration of market prices when available. If no market prices are available, valuations are determined by a discounted cash flow methodology using an internally calculated yield. The yield is comprised of a credit spread over a given benchmark. In all cases, the benchmark is an observable input. The credit spread contains both observable and unobservable inputs. Aegon starts by taking an observable credit spread from a similar bond of the given issuer, and then adjusts this spread based on unobservable inputs. These unobservable inputs may include subordination, liquidity and maturity differences. The weighted average credit spread used in valuation of corporate bonds has decreased to 2.6% (December 31, 2016: 3.1%).

If available, Aegon uses quoted market prices in active markets to determine the fair value of its Government debt investments, If Aegon cannot make use of quoted market prices, market prices from indices or quotes from third-party pricing services or brokers are used.

Tax credit investments

The fair value of tax credit investments is determined by using a discounted cash flow valuation technique, This valuation technique takes into consideration projections of future capital contributions and distributions, as well as future tax credits and the tax benefits of future operating losses. The present value of these cash flows is calculated by applying a discount rate. In general, the discount rate is determined based on the cash outflows for the investments and the cash inflows from the tax credits/tax benefits (and the timing of those cash flows), These inputs are unobservable in the market place. The discount rate used in valuation of tax credit investments increased to 5.8% (December 31, 2016: 5.6%).

Investment funds

Investment funds include real estate funds, private equity funds and hedge funds, The fair values of investments held in non-quoted investment funds are determined by management after taking into consideration information provided by the fund managers. Aegon reviews the valuations each month and performs analytical procedures and trending analyses to ensure the fair values are appropriate.

Derivatives

Where quoted market prices are not available, other valuation techniques, such as option pricing or stochastic modeling, are applied. The valuation techniques incorporate all factors that a typical market participant would consider and are based on observable market data when available. Models are validated before they are used and calibrated to ensure that outputs reflect actual experience and comparable market prices,

 

Unaudited    LOGO


Table of Contents

    

     24     

    

  

 

Fair values for exchange-traded derivatives, principally futures and certain options, are based on quoted market prices in active markets. Fair values for over-the-counter (“OTC”) derivatives represent amounts estimated to be received from or paid to a third party in settlement of these instruments. These derivatives are valued using pricing models based on the net present value of estimated future cash flows, directly observed prices from exchange-traded derivatives, other OTC trades, or external pricing services. Most valuations are derived from swap and volatility matrices, which are constructed for applicable indices and currencies using current market data from many industry standard sources. Option pricing is based on industry standard valuation models and current market levels, where applicable. The pricing of complex or illiquid instruments is based on internal models or an independent third party. For long-dated illiquid contracts, extrapolation methods are applied to observed market data in order to estimate inputs and assumptions that are not directly observable. To value OTC derivatives, management uses observed market information, other trades in the market and dealer prices.

Some OTC derivatives are so-called longevity derivatives. The payout of longevity derivatives is linked to publicly available mortality tables. The derivatives are measured using the present value of the best estimate of expected payouts of the derivative plus a risk margin. The best estimate of expected payouts is determined using best estimate of mortality developments. Aegon determined the risk margin by stressing the best estimate mortality developments to quantify the risk and applying a cost-of-capital methodology. The most significant unobservable input for these derivatives is the (projected) mortality development.

Aegon normally mitigates counterparty credit risk in derivative contracts by entering into collateral agreements where practical and in ISDA (International Swaps and Derivatives Association) master netting agreements for each of the Group’s legal entities to facilitate Aegon’s right to offset credit risk exposure. Changes in the fair value of derivatives attributable to changes in counterparty credit risk were not significant.

Embedded derivatives in insurance contracts including guarantees

All bifurcated guarantees for minimum benefits in insurance and investment contracts are carried at fair value. These guarantees include guaranteed minimum withdrawal benefits (GMWB) in the United States, United Kingdom and Japan which are offered on some variable annuity products and are also assumed from a ceding company; minimum investment return guarantees on insurance products offered in the Netherlands, including group pension and traditional products; variable annuities sold in Europe and Japan.

Since the price of these guarantees is not quoted in any market, the fair values of these guarantees are based on discounted cash flows calculated as the present value of future expected payments to policyholders less the present value of assessed rider fees attributable to the guarantees. Given the complexity and long-term nature of these guarantees which are unlike instruments available in financial markets, their fair values are determined by using stochastic models under a variety of market return scenarios. A variety of factors are considered including credit spread, expected market rates of return, equity and interest rate volatility, correlations of market returns, discount rates and actuarial assumptions. The most significant unobservable factor is discount rate. The credit spread used in the valuations of embedded derivatives in insurance contracts has decreased to 0.2% (December 31, 2016: 0.4%).

The expected returns are based on risk-free rates. Aegon added a premium to reflect the credit spread as required. The credit spread is set by using the credit default swap (CDS) spreads of a reference portfolio of life insurance companies (including Aegon), adjusted to reflect the subordination of senior debt holders at the holding company level to the position of policyholders at the operating company level (who have priority in payments to other creditors). Aegon’s assumptions are set by region to reflect differences in the valuation of the guarantee embedded in the insurance contracts.

Since many of the assumptions are unobservable and are considered to be significant inputs to the liability valuation, the liability included in future policy benefits has been reflected within Level III of the fair value hierarchy.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     25     

    

 

Effect of reasonably possible alternative assumptions

The effect of changes in unobservable inputs on fair value measurement were not significantly different than those that were applied to the consolidated financial statements as at and for the year ended December 31, 2016.

Fair value information about financial instruments not measured at fair value

The following table presents the carrying values and estimated fair values of financial assets and liabilities, excluding financial instruments which are carried at fair value on a recurring basis.

 

Fair value information about financial instruments not measured at fair value

 

 
EUR millions   Carrying
amount December 31,
2017
   

Total

estimated fair
value December 31,
2017

   

Carrying
amount December 31,

2016

   

Total

estimated fair
value December 31,
2016

 
   

Assets

         

Mortgage loans - held at amortized cost

    33,930       38,076       34,206       38,499  

Private loans - held at amortized cost

    3,642       4,181       3,166       3,569  

Other loans - held at amortized cost

    2,164       2,164       2,441       2,441  
   

Liabilities

         

Subordinated borrowings - held at amortized cost

    764       953       767       844  

Trust pass-through securities - held at amortized cost

    133       137       156       141  

Borrowings - held at amortized cost

    13,099       13,499       12,543       12,935  

Investment contracts - held at amortized cost

    16,665       17,031       19,217       19,748  

Financial instruments for which carrying value approximates fair value

Certain financial instruments that are not carried at fair value are carried at amounts that approximate fair value, due to their short-term nature and generally negligible credit risk. These instruments include cash and cash equivalents, short-term receivables and accrued interest receivable, short-term liabilities, and accrued liabilities. These instruments are not included in the table above.

18. Deferred expenses

 

                

EUR millions

    Dec. 31, 2017       Dec. 31, 2016  
     

Deferred policy acquisition costs (DPAC) for insurance contracts and investment contracts with discretionary participation features

    9,688       10,882  

Deferred cost of reinsurance

    41       60  

Deferred transaction costs for investment management services

    406       481  

Total deferred expenses

    10,135       11,423  

Deferred expenses are predominantly impacted by regular amortisations, adjustments for differences between projections versus realization of deferral schemes and unfavorable currency translation adjustments. Deferred Policy acquisition costs were further impacted by the divestment of the pay-out annuity and BOLI/COLI businesses in the Americas, which resulted in a write off of EUR 205 million.

 

Unaudited    LOGO


Table of Contents

    

     26     

    

  

 

19. Intangible assets

 

                

EUR millions

    Dec. 31, 2017       Dec. 31, 2016  
     

Goodwill

    293       294  

VOBA

    1,153       1,399  

Future servicing rights

    99       64  

Software

    51       50  

Other

    36       12  

Total intangible assets

    1,633       1,820  

Intangible assets, are predominantly impacted by periodic amortization of balances (except for goodwill) and changes in foreign exchange rates. The acquisition of Cofunds Ltd. in January 2017 resulted in recognition of goodwill amounting to EUR 56 million and of “customer intangibles” (included in the line “Other”) amounting to EUR 29 million. Increase in goodwill was offset by the divestment of UMG on November 1, 2017 which led to a decrease of EUR 27 million and the negative impact of net exchange differences of EUR 31 million. The divestment of the payout annuity and BOLI/COLI businesses in the Americas and UMG in the Netherlands resulted in a write off of VOBA of EUR 11 million. Future servicing rights increased by EUR 36 million mainly due to the acquisition of Nordea second-pillar pension fund in Poland. Refer to note 29 Acquisitions/divestments.

20. Share capital

                

EUR millions

    Dec. 31, 2017       Dec. 31, 2016  
     

Share capital - par value

    322       319  

Share premium

    7,731       7,873  

Total share capital

    8,053       8,193  
     

Share capital - par value

       

Balance at January 1

    319       328  

Dividend

    3       1  

Shares withdrawn

    -       (10

Balance

    322       319  
     

Share premium

       

Balance at January 1

    7,873       8,059  

Share dividend

    (142     (186

Balance

    7,731       7,873  

Basic and diluted earnings per share

 

           
                              

EUR millions

    4Q 2017       4Q 2016       FY 2017       FY 2016  
     

Earnings per share (EUR per share)

           

Basic earnings per common share

    0.46       0.21       1.08       0.22  

Basic earnings per common share B

    0.01       0.01       0.03       0.01  

Diluted earnings per common share

    0.46       0.21       1.08       0.22  

Diluted earnings per common share B

    0.01       0.01       0.03       0.01  

Earnings per share calculation

           

Net income / (loss) attributable to owners of Aegon N.V.

    986       470       2,361       586  

Coupons on other equity instruments

    (32     (33     (131     (133

Earnings attributable to common shares and common shares B

    953       437       2,230       453  
     

Earnings attributable to common shareholders

    947       434       2,214       449  

Earnings attributable to common shareholders B

    7       3       16       3  
     

Weighted average number of common shares outstanding (in millions)

    2,052       2,033       2,042       2,048  

Weighted average number of common shares B outstanding (in millions)

    580       568       575       575  

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     27     

    

 

Final dividend 2017

It will be proposed to the Annual General Meeting of Shareholders on May 18, 2018, absent unforeseen circumstances, to pay a final dividend for the year 2017 of EUR 0.14 per common share. After taking into account the interim dividend 2017 of EUR 0.13 per common share, this will result in a total 2017 dividend of EUR 0.27 per common share. Proposed final dividend for the year and proposed total 2017 dividend per common share B amount to 1/40th of the dividend paid on common shares.

Interim dividend 2017

On September 13, 2017, Aegon paid an interim dividend 2017 in cash or stock at the election of the shareholder. The cash dividend amounted to EUR 0.13 per common share and the stock dividend amounted to one new Aegon common share for every 36 common shares held. Dividend paid on common shares B amounted to 1/40th of the dividend paid on common shares. The interim dividend 2017 is paid in cash or in stock at the election of the shareholder. The stock fraction is based on Aegon’s average share price as quoted on Euronext Amsterdam, using the high and low of each of the five trading days from September 4 up to and including September 8, 2017. The value of the stock dividend and the cash dividend are approximately equal in value and 43% of shareholders elected to receive the stock dividend. The remaining 57% opted for cash dividend. The average share price calculated on this basis amounted to EUR 4.7033. The stock dividend and the cash dividend are approximately equal in value.

Final dividend 2016

The Annual General Meeting of Shareholders on May 19, 2017, approved a final dividend for the year 2016 of EUR 0.13 per common share in either cash or stock. The stock dividend amounted to one new Aegon common share for every 35 common shares held. After taking into account the interim dividend 2016 of EUR 0.13 per common share, this resulted in a total 2016 dividend of EUR 0.26 per common share. Final dividend for the year and total 2016 dividend per common share B amounted to 1/40th of the dividend paid on common shares.

The final dividend 2016 is paid in cash or in stock at the election of the shareholder. The value of the stock dividend and the cash dividend are approximately equal in value and 46% of shareholders elected to receive the stock dividend. Those who elected to receive a stock dividend received one Aegon common share for every 35 common shares held. The stock fraction is based on Aegon’s average share price as quoted on Euronext Amsterdam, using the high and low of each of the five trading days from June 12 up to and including June 16, 2017. The average share price calculated on this basis amounted to EUR 4.5254. The dividend was paid as of June 23, 2017.

Share buyback

To neutralize the dilutive effect of the 2016 final dividend and the 2017 interim stock dividend paid in shares, Aegon executed a program to repurchase 51,864,626 common shares. Aegon committed to the repurchase of the common shares by engaging a third party to execute the transactions on its behalf. These transactions commenced on October 2, 2017, and were completed on December 15, 2017, at an average price of EUR 5.0950 per share. These shares are being held as treasury shares and will be used to cover future stock dividends.

21. Insurance contracts

Insurance contracts decreased by EUR 8.8 billion to EUR 110.8 billion compared to December 31, 2016 mainly due to changes in foreign exchange rates.

22. Insurance contracts for account of policyholders

Insurance contracts for account of policyholders increased by EUR 1.2 billion to EUR 122.2 billion compared to December 31, 2016. An increase in insurance liabilities driven by received gross premiums and deposits, and by an increase in the market value of underlying assets, was partly offset by changes in foreign exchange rates, insurance liabilities released and the reclassification to held for sale of the liabilities related to Aegon Ireland plc. of EUR 1.3 billion.

 

Unaudited    LOGO


Table of Contents

    

     28     

    

  

 

23. Investment contracts

Investment contracts decreased by EUR 2.6 billion to EUR 16.9 billion compared to December 31, 2016 mainly due to an accelerated reduction of run-off balances in the first quarter and changes in foreign exchange rates.

24. Investment contracts for account of policyholders

The decrease of Investment contracts for account of policyholders of EUR 10.3 billion to EUR 74.4 billion compared to December 31, 2016 includes the reclassification of the liabilities related to Aegon Ireland plc. as held for sale. Please refer to note 26 Assets and Liabilites held for sale for more details. In addition, changes in foreign exchange rates also contributed to the decrease.

25. Borrowings

 

    

EUR millions

    Dec. 31, 2017       Dec. 31, 2016  
     

Capital funding

    2,280       2,386  

Operational funding

    11,355       10,766  

Total borrowings

    13,635       13,153  

Included in borrowings is EUR 536 million relating to borrowings measured at fair value (December 31, 2016: EUR 610 million).

During 2017, the operational funding increased EUR 0.6 billion due to new FHLB advances in the first quarter and a covered bond issuance in the Netherlands of EUR 0.5 billion in the fourth quarter. This was partly offset by two redemptions in the fourth quarter: Seacure 12 in the Netherlands of EUR 0.9 billion and operational funding supporting a captive insurance company, which was dissolved following the divestment of a block of life reinsurance business in the Americas of EUR 0.4 billion. Next to this there was a decrease of EUR 0.5 billion as result of foreign exchange impacts on the US dollar positions as a result of the strengthening of the euro.

On July 18, 2017, Aegon redeemed unsecured notes with a coupon of 3%, issued in 2012. The principal amount of EUR 500 million was repaid with accrued interest. On August 30, 2017, Aegon issued EUR 500 million senior unsecured notes, due August 30, 2018. The notes were issued under Aegon’s USD 6 billion debt issuance program at a price of 100.157%, and carry a coupon of 0.00%.

26. Assets and Liabilities held for sale

Assets and liabilities held for sale include disposal groups whose carrying amount will be recovered principally through a sale transaction rather than through continuing operations. This relates to businesses for which a sale is agreed upon or a sale is highly probable at the balance sheet date but for which the transaction has not yet fully closed. As per December 31, 2016 certain assets and liabilities from Aegon UK (as described below) were included in Assets and Liabilites held for sale, which is not the case anymore as per December 31, 2017. As per December 31, 2017, the assets and liabilities of Aegon Ireland (as described below) were included in Assets and Liabilites held for sale.

Aegon UK

In 2016, Aegon reclassed certain assets and liabilities to the assets and liabilities held for sale line, following the sale of its UK annuity portfolio. In 2017, following court approval on the Part VII transfers, the sale of the annuity portfolio to Rothesay Life and Legal & General was completed. As a consequence the assets held for sale which were on the balance sheet per December 31, 2016 of EUR 8,705 million and the liabilities held for sale on the balance sheet per December 31, 2016 of EUR 8,816 million have been derecognized. The UK annuity portfolio is included in the United Kingdom operating segment. Also refer to note 29 Acquisitions/divestments.

 

LOGO    Unaudited


Table of Contents

    

     29     

    

  

 

Aegon Ireland

On August 9, 2017, Aegon agreed to sell Aegon Ireland plc. The sales price will amount to 81% of the Solvency II Own Funds of Aegon Ireland at the end of 2017. As the transaction is contingent on certain closing and market conditions until closing of the transaction, the book loss is uncertain. The transaction is subject to customary regulatory approvals and is expected to close in the first quarter of 2018.

Aegon Ireland is included in the United Kingdom operating segment.

The table below presents the major classes of assets and liabilities of Aegon Ireland plc included in Assets classified as held for sale and Liabilities classified as held for sale on the condensed consolidated statement of financial position:

 

 

Condensed consolidated statement of financial position

Entities held for sale

 

      

EUR millions

    Dec. 31, 2017  
   

Assets

   

Cash and cash equivalents

    260  

Investments

    139  

Investments for account of policyholders

    4,775  

Derivatives

    57  

Deferred expenses

    6  

Other assets and receivables

    12  

Total assets

    5,249  
   

Liabilities

   

Insurance contracts for account of policyholders

    1,346  

Investment contracts for account of policyholders

    3,518  

Derivatives

    74  

Other liabilities

    65  

Total liabilities

    5,003  

Fair value measurement

The fair value hierarchy of financial assets and liabilities (measured at fair value), which are presented as held for sale is included below. The fair value hierarchy consists of three levels. Reference is made to note 16 for more details on the fair value hierarchy.

 

 

Fair value hierarchy

 

                           
         
EUR millions   Level I     Level II     Level III     Total  

As at December 31, 2017

           
     

Financial assets carried at fair value

           

Fair value through profit or loss

           

Shares

    139       -       -       139  

Investments for account of policyholders

    1,699       3,076       -       4,775  

Derivatives

    -       57       -       57  

Total Fair value through profit or loss

    1,837       3,133       -       4,971  

Total financial assets at fair value

    1,837       3,133       -       4,971  
     

Financial liabilities carried at fair value

           

Investment contracts for account of policyholders

    -       3,518       -       3,518  

Derivatives

    -       41       33       74  

Total financial liabilities at fair value

    -       3,559       33       3,592  

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     30     

    

 

27. Capital management and solvency

Capital adequacy

The capitalization of the Aegon Group and its operating units is managed in relation to the most stringent of local regulatory requirements, rating agency requirements and/or self-imposed criteria. Aegon manages its Solvency II capital in relation to the required capital. Under Aegon’s capital management framework the own funds are managed such that the Group Solvency II ratio remains within the target range of 150% - 200%. This target range has been updated (previous target range: 140% - 170%) in line with a revision of Aegon’s group capital management policy.

Together with this capital policy update, Aegon agreed with the Dutch Central Bank (DNB) to apply a revised method to calculate the Solvency II contribution of the Aegon Americas Insurance entities under Deduction & Aggregation (D&A), affecting Aegon’s tiering of capital, retrospectively as of 2Q, 2017. It includes lowering of the conversion factor from 250% to 150% RBC Company Action Level and reducing own funds by a 100% RBC Company Action Level requirement to reflect transferability restrictions. The methodology is subject to annual review. This methodology is consistent with EIOPA’s guidance on group solvency calculation in the context of equivalence, and in line with methods applied by other European peer companies. As a consequence, this adjustment improves the comparability of capital positions of European insurance groups with substantial insurance activities in the Americas. The impact on Tiering is included in the table in the Capital quality section below.

Capital quality

Aegon’s capital consists of 3 Tiers as an indication of its quality, with Tier 1 capital ranking highest. The Group own funds do not include any impact from contingent liabilities potentially arising from unit-linked products sold, issued or advised on by Aegon in the Netherlands in the past as the potential liability cannot be reliably quantified at this point. Further, the available own funds number reflects Aegon’s interpretation of Solvency II requirements which is subject to supervisory review.

The below table provides the composition of Aegon’s available own funds across Tiers:

 

       
    

December 31, 2017 1
Available

own funds

   

December 31, 20161
Available

own funds

   

December 31, 2016
Available

own funds

 
     

Tier 1 - unrestricted

    10,428       10,081       10,656  

Tier 1 - restricted

    3,540       3,817       3,817  

Tier 2

    1,213       1,291       2,008  

Tier 3

    448       768       1,638  

Total available own funds

    15,628       15,957       18,119  

1 The tiering information is based on the revised method which was confirmed by DNB on August 8, 2017.

On a comparable basis, under the revised methodology Aegon’s own funds reduced by EUR 2.2 billion at December 31, 2016. This is reflected through eliminating deferred tax balances, recorded in Tier 3 for an amount of EUR 0.9 billion and Tier 2 for an amount of EUR 0.7 billion and eliminating Tier 1 - unrestricted of EUR 0.6 billion.

As at December 31, 2017, Tier 1 capital accounted for 89% of own funds (2016: 87%; pro forma number based on revised method), including EUR 3,047 million of junior perpetual capital securities (2016: EUR 3,309 million) and EUR 493 million of perpetual cumulative subordinated bonds (2016: EUR 508 million) which are both classified as grandfathered restricted Tier 1 capital.

The grandfathered restricted Tier 1 and Tier 2 capital instruments are grandfathered such that they are considered as capital under the Solvency II framework for up to 10 years as from January 1, 2016.

Tier 3 capital as of December 31, 2017, is comprised of deferred tax assets balances related to Solvency II entities.

 

Unaudited    LOGO


Table of Contents

    

     31     

    

  

 

 

IFRS-EU equity compared to Solvency II own funds

 

                    

EUR millions

    December 31, 2017  1      December 31, 2016  1      December 31, 2016  
       

Shareholders’ Equity

    20,573       20,913       20,913  

IFRS adjustments for Other Equity Instruments and non controlling interests

    3,813       3,821       3,821  

Group Equity

    24,386       24,734       24,734  

Solvency II revaluations

    (5,701     (5,634     (5,634

Excess of Assets over Liabilities

    18,685       19,100       19,100  

Availability adjustments

    (606     (361     (361

Fungibility restrictions 2

    (693     (619     (619

Transferability restrictions 3

    (1,758     (2,162     -  

Available own funds

    15,628       15,957       18,119  

1 The own funds information is based on the revised method which was confirmed by DNB on August 8, 2017.

2 Amongst others, this contains the exclusion of Aegon Bank

3 This includes the transferability restriction related to the new RBC CAL conversion methodology

The Solvency II negative revaluations of EUR 5,701 million (2016: EUR 5,634 million negative) stem from the difference in valuation between IFRS-EU and Solvency II frameworks, which can be grouped into three categories:

 

t   Items that are not recognized under Solvency II. The most relevant examples of this category for Aegon include Goodwill, DPAC and other intangible assets (EUR 2,019 million, 2016: EUR 2,118 million);
t   Items that have a different valuation treatment between IFRS-EU and Solvency II. Solvency II is a market consistent framework hence all assets and liabilities are to be presented at fair value while IFRS-EU also includes other valuation treatments in addition to fair value. The most relevant examples of this category for Aegon Group include Loans and Mortgages, Reinsurance Recoverables and Technical provisions. The revaluation difference stemming from this category amounted to EUR (1,701) million (2016: EUR(1,924) million) compared to the IFRS-EU Statement of Financial Position;
t   The Net Asset Value of subsidiaries that are included under the Deduction & Aggregation method (on provisional equivalence or Standard Formula basis) in the Group Solvency II results. The revaluation difference stemming from this category amounted to EUR (6,019) million (2016: EUR (5,828) million) compared to the IFRS-EU Statement of Financial Position.

The availability adjustments are changes to the availability of own funds of Aegon Group in accordance with Solvency II requirements. Examples include the adjustments for subordinated liabilities, ring-fenced fund, treasury shares and foreseeable dividend (if applicable).

Fungibility restrictions limit the availability of own funds on Aegon Group level as prescribed by Supervisory Authorities. These limitations refer to charitable trusts in the Americas for which the local Supervisory Authority could limit the upstream of capital to the Group, and Aegon Bank which is under a different regulatory regime but under the same Supervisory Authority and therefore excluded for Solvency II purposes.

Finally, Transferability restrictions reflect the restrictions on the Americas Life Companies DTA and capping of Tier 1 unrestricted own funds as a consequence of the new RBC CAL conversion methodology as described above.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     32     

    

 

28. Commitments and contingencies

As previously disclosed, the U.S. Securities and Exchange Commission (SEC) is conducting a formal investigation related to certain investment strategies offered through mutual funds, variable products and separately managed accounts. These strategies used quantitative models developed by one of the former portfolio managers of Aegon’s US investment management business unit. Among other things, the investigation relates to errors in those quantitative models and their implementation as well as in related disclosures. The funds and strategies under review were sub-advised, advised or marketed by Aegon’s US group companies. The models are no longer being used, although some of the funds are still being offered. The quantative strategies are no longer being offered. Aegon discovered the errors, notified the SEC, conducted a comprehensive review and has been cooperating fully with the SEC’s investigation. In anticipation of a possible settlement, Aegon has taken a provision of EUR 85 million in the fourth quarter of 2017. This amount is partly recorded in the Americas (EUR 45 million) and partly in Asset Management (EUR 40 million). Aegon currently expects the investigation to conclude in 2018.

Government investigations, including this one, may result in the institution of administrative, injunctive or other proceedings and/or the imposition of monetary fines, penalties and/or disgorgement, as well as other remedies, sanctions, damages and restitutionary amounts. While Aegon is unable to predict what action, if any, the SEC might take or whether a settlement will occur and is unable to predict with certainty the costs to or other impact on Aegon of any such action, there can be no assurances that this matter or other government investigations will not have a material and adverse effect on Aegon’s reputation, financial position, results of operations or liquidity.

There have been no other material changes in contingent assets and liabilities as reported in the 2016 consolidated financial statements of Aegon.

29. Acquisitions / divestments

On January 1, 2017, Aegon completed the acquisition of Cofunds Ltd., following regulatory approval. The purchase of the Cofunds Ltd. business was done through a sale and purchase agreement to acquire all the shares and platform assets. The total consideration of the acquisition amounted to GBP 147 million (EUR 171 million). The fair value of the net assets amounted to GBP 99 million (EUR 116 million), of which GBP 25 million (EUR 29 million) related to “customer intangibles”, resulting in goodwill of GBP 48 million (EUR 56 million). The value of the transferred customer investments under management as per January 1, 2017 amounted to approximately GBP 82 billion (EUR 96 billion) and is not recognized on Aegon’s statement of financial position.

On June 28, 2017, Aegon completed its transaction to divest its two largest run-off businesses in the Americas, the payout annuity business and Bank Owned Life Insurance/ Corporate Owned Life Insurance business (BOLI/COLI). Under the terms of the agreement, Aegon’s Transamerica life subsidiaries has reinsured USD 14 billion of liabilities. The transaction resulted in a book gain of USD 250 million (EUR 231 million), reported in the line other income in the condensed consolidated income statement. The book gain consisted of a loss on the reinsurance transaction which is more than offset by the reclassification of gains from Other Comprehensive Income following the disposal of assets to fund the transaction.

The loss on the reinsurance transaction amounted to USD 1,813 million (EUR 1,675 million) being the difference of the reinsurance premium paid and the reinsurance asset received related to the insurance liabilities. Upon disposal an amount of USD 979 million (EUR 905 million) and USD 1,018 million (EUR 941 million) respectively related to revaluation reserves and cash flow hedging reserves has been reclassified from Other Comprehensive Income into the income statement. Gains on sale of certain assets carried at amortized cost backing the insurance liabilities amount to USD 94 million (EUR 87 million). Other expenses related to the transaction, including cost of sale, amounted to USD 28 million (EUR 26 million).

 

Unaudited    LOGO


Table of Contents

    

     33     

    

  

 

On June 30, 2017, following court approval on the Part VII transfer, the sale of the annuity portfolio to Rothesay Life has been completed. For more details related to the sale of the UK annuity portfolio, refer to the 2016 consolidated financial statements.

On August 2, 2017, Aegon Poland has received approval by the Polish Financial Supervision Authority to take over the management of the Nordea second-pillar pension fund.

On August 9, 2017, Aegon agreed to sell Aegon Ireland plc. The sales price will amount to 81% of the Solvency II Own Funds of Aegon Ireland at the end of 2017. This transaction further optimizes its portfolio of businesses. As the transaction is contingent on certain closing and market conditions until closing of the transaction, the book loss is uncertain. This divestment is expected to have an immaterial impact on income before tax and underlying earnings before tax going forward. The transaction is subject to customary regulatory approvals and is expected to close in the first quarter of 2018.

On September 22, 2017, following court approval on the Part VII transfer, the sale of the annuity portfolio to Legal & General has been completed. For more details related to the sale of the UK annuity portfolio, refer to the 2016 consolidated financial statements. On November 1, 2017, Aegon completed the sale of Unirobe Meeùs Groep (UMG), an independent financial advisory group, for a total consideration of EUR 295 million. The divestment lead to a book gain of EUR 208 million, which was reported in Other income in the fourth quarter. As a consequence of this transaction annual income before tax and underlying earnings before tax will decrease by approximately EUR 20 million going forward from the 2017 level.

On December 28, 2017, Aegon agreed to divest a block of life reinsurance business to SCOR and to dissolve a related captive insurance company. Under the terms of the agreement, Aegon’s Transamerica life subsidiaries will reinsure approximately USD 750 million of liabilities to SCOR. The transaction covers approximately half of the life reinsurance business that Transamerica retained after it divested the vast majority of its life reinsurance business to SCOR in 2011.

30. Post reporting date events

On January 11, 2018, Aegon announced that its subsidiary in the Americas, Transamerica, has entered into an agreement with Tata Consultancy Services (TCS) to administer the company’s US insurance and annuity business lines. The agreement is expected to be completed by the second quarter 2018.

 

LOGO    Unaudited


Table of Contents
 

    

 Condensed Consolidated Interim Financial Statements 4Q 2017  

    

  

    

     34     

    

 

Disclaimers

Cautionary note regarding non-IFRS-EU measures

This document includes the following non-IFRS-EU financial measures: underlying earnings before tax, income tax and income before tax. These non-IFRS-EU measures are calculated by consolidating on a proportionate basis Aegon’s joint ventures and associated companies. The reconciliation of these measures to the most comparable IFRS-EU measure is provided in note 3 ‘Segment information’ of Aegon’s Condensed Consolidated Interim Financial Statements. Aegon believes that these non-IFRS-EU measures, together with the IFRS-EU information, provide meaningful supplemental information about the underlying operating results of Aegon’s business including insight into the financial measures that senior management uses in managing the business.

Forward-looking statements

 

t   The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:

 

t   Changes in general economic conditions, particularly in the United States, the Netherlands and the United Kingdom;
t   Changes in the performance of financial markets, including emerging markets, such as with regard to:
  The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios;
  The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and
  The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;
t   Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties;
t   Consequences of a potential (partial) break-up of the euro;
t   Consequences of the anticipated exit of the United Kingdom from the European Union;
t   The frequency and severity of insured loss events;
t   Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products;
t   Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;
t   Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;
t   Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;
t   Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;
t   Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets;
t   Changes in laws and regulations, particularly those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers;
t   Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates;
t   Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII);
t   Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations;
t   Acts of God, acts of terrorism, acts of war and pandemics;
t   Changes in the policies of central banks and/or governments;
t   Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition;
t   Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the premium writings, policy retention, profitability and liquidity of its insurance subsidiaries;
t   The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;
t   Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;
t   As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, a computer system failure or security breach may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows;
t   Customer responsiveness to both new products and distribution channels;
t   Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products;
t   Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results and shareholders’ equity;
t   Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results;
t   The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;
t   Catastrophic events, either manmade or by nature, could result in material losses and significantly interrupt Aegon’s business;
t   Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess capital and leverage ratio management initiatives; and
t   This press release contains information that qualifies, or may qualify, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

Unaudited    LOGO


Table of Contents

    

     35     

    

  

 

Corporate and shareholder information

 

 

Headquarters      
Aegon N.V.      
P.O. Box 85      
2501 CB The Hague      
The Netherlands      
+ 31 (0) 70 344 32 10      
aegon.com      

Group Corporate Communications & Investor Relations

 

Media relations      
+ 31 (0) 70 344 83 44      
gcc@aegon.com      
Investor relations      
+ 31 (0) 70 344 83 05      
or 877 548 96 68 - toll free, USA only   
ir@aegon.com      

Publication dates quarterly results 2018

August 16, 2018    Results first half year 2018   
February 14, 2019    Results second half year 2018   

Aegon’s 4Q 2017 press release and Financial Supplement are available on aegon.com.

About Aegon

Aegon’s roots go back almost 175 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world’s leading financial services organizations, providing life insurance, pensions and asset management. Aegon’s purpose is to help people achieve a lifetime of financial security. More information: aegon.com.